EGFR and neoplasm: Several clinical trials combining KRASi with inhibitors of upstream (i.e. SHP2 and SOS1) and downstream (i.e. MEK, ERK, mTOR, PI3K, AKT) RAS effectors, as well as with RTK inhibitors like EGFR or even with ICIs are underway (Table 1).351,374 In addition to intensifying inhibition of the RAS signaling network, researchers have explored combinations that target downstream events within tumor cells.